Argatroban Antithrombin Anticoagulant
E-mail to a ColleagueArgatroban Site Map
Search Argatroban
Argatroban Home

About Argatroban

About Heparin-Induced Thrombocytopenia (HIT)
Underdiagnosis of Heparin-Induced Thrombocytopenia (HIT)
When to Suspect HIT
HIT & PCI
Heparin-Induced Thrombocytopenia FAQs
What the Experts are Saying about HIT
HIT Laboratory Testing
Educational Web Resorces on HIT
Argatroban & HIT Case Studies

Abstracts, News & Events About Argatroban

Argatroban Materials, Tools & Resources

CME Web Sites

Important Safety Information About Argatroban

Dosing & Indications About Argatroban

Argatroban Dosing Calculator

Hematology Case Presentation
The diagnosis of HIT should be made first on clinical grounds. Correlation of clinical findings with appropriate laboratory results may be helpful in confirming the results in many patients. HIT antibodies causes platelets to aggregate and to release serotonin. A positive serological test can be used to support the clinical suspicion.

There are three types of laboratory assays available:
Functional assay (SRA or serotonin release assay)
Platelet aggregation assay such as the HIPA (heparin-induced platelet aggregation)
Immunoassays such as ELISA (Enzyme-Linked Immunoassay) and PIFA® (Particle ImmunoFiltration Assay)

The functional assay (SRA) is performed by measuring radioactive serotonin release from washed platelets in the presence of the patient’s serum and an appropriate concentration of heparin. The HIPA measures the activity of the antibody/PF4/heparin complex.[38] Immunoassays detect the presence of HIT antibodies. [38]

Studies performed in the 1980s demonstrated that platelet aggregation assays are much less sensitive than the SRA. [38]

How do SRA, HIPA and immunoassays compare?

The immunoassays are more likely to detect clinically insignificant HIT antibodies, compared with the more sensitive washed platelet aggregation assays. Therefore, these assays are more likely to be falsely positive than the SRA. On the other hand, a negative antigen assay is better at ruling out the presence of antibodies.[38]

How is the more recent PIFA® method different from other testing methods?

Most testing methods take hours to perform. Because of the turnaround time and the special instrumentation needed, most tests are not conducive to cost-effectively or efficiently processing single patient samples. PIFA® is a single-use, single patient test that can determine a patient’s HIT antibody status in approximately 10 minutes. [41, 42]


Comparative chart of laboratory testing for HIT[38-42]
TestAdvantages Disadvantages
Functional assay (SRA)Sensitivity: high
Specificity: high
(false positives are rare)
Technically demanding (radioisotopes)
Not readily available
Heparin-induced platelet aggregation (HIPA) Specificity: high
Published clinical history
Sensitivity: low
Technique-dependent
ELISASensitivity: high
Technically easy
Rapid turnaround time
Specificity: low
(false positives common for some populations)
PIFA®Sensitivity: high
Specificity: high
Technically easy
Rapid turnaround time
Limited clinical history
Positive and negative controls not provided with assay.
PIFA is a registered trademark of Akers Biosciences, Inc., Thorofare, NJ. www.akersbiosciences.com

The Argatroban.com Web site contains links to third-party Web sites on the Internet. These links are provided as a service to individuals interested in more information in HIT. These sites are not part of this GlaxoSmithKline (GSK) Web site. The content and materials in these third-party Web sites are not produced or endorsed by GSK and may refer to uses of our products that are not recommended by GSK.